FREELINE - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 79252849
Serial Number
79252849
Registration Number
5974485
Word Mark
FREELINE
Status
700 - Registered
Status Date
2020-02-04
Filing Date
2018-11-19
Registration Number
5974485
Registration Date
2020-02-04
Mark Drawing
5000 - Illustration: Drawing with word(s)/letter(s)/number(s) in Stylized form Typeset
Published for Opposition Date
2019-11-19
Attorney Name
Samantha M. Quimby
Law Office Assigned Location Code
M40
Employee Name
REGAN, JOHN B
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the word "FREELINE" in stylised text.
Goods and Services
Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
Goods and Services
Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
Pseudo Mark
FREE LINE
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-03-04
Primary Code
005
International Class
040 - Treatment of materials. - Treatment of materials.
US Class Codes
100, 103, 106
Class Status Code
6 - Active
Class Status Date
2019-03-04
Primary Code
040
Current Trademark Owners
Party Name
Freeline Therapeutics Limited
Party Type
30 - Original Registrant
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Freeline Therapeutics Limited
Party Type
30 - Original Registrant
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Party Name
Freeline Therapeutics Limited
Party Type
20 - Owner at Publication
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Party Name
Freeline Therapeutics Limited
Party Type
10 - Original Applicant
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Samantha M. Quimby
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship TypeReel Number
Prior Registration5225203
International Registrations
International Registration Number
1452036
International Registration Date
2018-11-19
International Publication Date
2019-02-28
International Renewal Date
2028-11-19
Auto Protection Date
2020-08-28
International Status
001 - Request for extension of protection established
International Status Date
2019-02-28
Priority Claimed In
False
First Refusal In
True
Trademark Events
Event DateEvent Description
2019-02-28SN ASSIGNED FOR SECT 66A APPL FROM IB
2019-03-01LIMITATION FROM ORIGINAL APPLICATION ENTERED
2019-03-04NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2019-03-04ASSIGNED TO EXAMINER
2019-03-08APPLICATION FILING RECEIPT MAILED
2019-03-11NON-FINAL ACTION WRITTEN
2019-03-12NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
2019-03-21REFUSAL PROCESSED BY MPU
2019-03-21NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
2019-04-06REFUSAL PROCESSED BY IB
2019-09-20TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-09-20CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-09-20TEAS/EMAIL CORRESPONDENCE ENTERED
2019-10-10APPROVED FOR PUB - PRINCIPAL REGISTER
2019-10-17ASSIGNED TO LIE
2019-10-30NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2019-10-30NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
2019-10-30NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
2019-11-15NOTIFICATION PROCESSED BY IB
2019-11-19PUBLISHED FOR OPPOSITION
2019-11-19OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2020-02-04REGISTERED-PRINCIPAL REGISTER
2020-05-04FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
2020-05-18FINAL DISPOSITION PROCESSED
2020-05-18FINAL DISPOSITION NOTICE SENT TO IB
2020-06-05FINAL DECISION TRANSACTION PROCESSED BY IB